UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.12B |
| 2 |
Apple
AAPL
|
+$1.08B |
| 3 |
Microsoft
MSFT
|
+$1.05B |
| 4 |
Nike
NKE
|
+$1.03B |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$821M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$389M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$383M |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$348M |
| 4 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$263M |
| 5 |
NRG Energy
NRG
|
+$237M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.8% |
| 2 | Financials | 8.25% |
| 3 | Healthcare | 6.4% |
| 4 | Consumer Discretionary | 5.85% |
| 5 | Communication Services | 4.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TRML
6001
DELISTED
Tourmaline Bio
TRML
| $125K | ﹤0.01% |
9,700
+6,879
| +244% | +$111K |
|
6002
Neurogene
NGNE
$712M
| $125K | ﹤0.01% |
3,423
-6,295
| -65% | -$222K |
|
6003
Chunghwa Telecom
CHT
$33B
| $125K | ﹤0.01% |
3,226
-31,934
| -91% | -$1.24M |
|
6004
Veritone
VERI
$122M
| $124K | ﹤0.01% |
55,007
-64,263
| -54% | -$228K |
|
6005
Unity Bancorp
UNTY
$599M
| $124K | ﹤0.01% |
4,200
-4,274
| -50% | -$115K |
|
6006
Bally's
BALY
$658M
| $124K | ﹤0.01% |
10,375
-26,915
| -72% | -$344K |
|
6007
Magnachip Semiconductor
MX
$145M
| $124K | ﹤0.01% |
25,479
-7,306
| -22% | -$36.7K |
|
|
TEI
6008
Templeton Emerging Markets Income Fund
TEI
$321M
| $124K | ﹤0.01% |
23,280
-2,308
| -9% | -$12.4K |
|
6009
Black Diamond Therapeutics
BDTX
$112M
| $124K | ﹤0.01% |
26,534
+22,263
| +521% | +$120K |
|
6010
Innovator Growth-100 Power Buffer ETF April
NAPR
$212M
| $124K | ﹤0.01% |
+2,595
| New | +$119K |
|
6011
JPMorgan US Tech Leaders ETF
JTEK
$4.44B
| $123K | ﹤0.01% |
+1,783
| New | +$116K |
|
6012
GCM Grosvenor
GCMG
$820M
| $123K | ﹤0.01% |
12,641
-29,899
| -70% | -$288K |
|
6013
Invesco Zacks Multi-Asset Income ETF
CVY
$124M
| $123K | ﹤0.01% |
4,910
-19
| -0.4% | -$481 |
|
6014
Sierra Bancorp
BSRR
$525M
| $123K | ﹤0.01% |
5,500
-9,047
| -62% | -$185K |
|
6015
Vicor
VICR
$10.2B
| $123K | ﹤0.01% |
3,709
-17,456
| -82% | -$602K |
|
|
CXH
6016
DELISTED
MFS Investment Grade Municipal Trust
CXH
| $123K | ﹤0.01% |
15,567
-108
| -0.7% | -$815 |
|
6017
Lyell Immunopharma
LYEL
$360M
| $123K | ﹤0.01% |
4,241
-5,718
| -57% | -$272K |
|
6018
Build-A-Bear
BBW
$462M
| $123K | ﹤0.01% |
4,849
-8,833
| -65% | -$249K |
|
6019
Innodata
INOD
$2.04B
| $122K | ﹤0.01% |
8,235
-20,615
| -71% | -$214K |
|
6020
Karyopharm Therapeutics
KPTI
$48M
| $122K | ﹤0.01% |
9,379
-7,617
| -45% | -$126K |
|
|
JOF
6021
Japan Smaller Capitalization Fund
JOF
$350M
| $122K | ﹤0.01% |
16,078
+7,078
| +79% | +$54.5K |
|
6022
Park-Ohio Holdings
PKOH
$761M
| $121K | ﹤0.01% |
4,692
-5,064
| -52% | -$129K |
|
|
BRNS
6023
Barinthus Biotherapeutics
BRNS
$24.5M
| $121K | ﹤0.01% |
86,653
+85,106
| +5,501% | +$192K |
|
6024
Tyra Biosciences
TYRA
$1.58B
| $121K | ﹤0.01% |
7,575
-6,597
| -47% | -$114K |
|
6025
Reborn Coffee
REBN
$12.4M
| $121K | ﹤0.01% |
+17,363
| New | +$57.5K |
|
Similar funds
UBS Group's Q2 2024 Portfolio in Review
As of Q2 2024, UBS Group held 10,501 positions worth $405B, up 0.81% from $402B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
UBS Group's Q2 2024 filing shows 1,231 new, 3,688 increased, 4,131 reduced and 1,043 closed positions. Its largest new stake was SLB Ltd: 10,925,731 shares worth $515M. The largest sale was BioMarin Pharmaceuticals, an estimated $389M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.
- UBS Group's largest Q2 2024 buy was SLB Ltd: 10,925,731 shares worth $515M.
- UBS Group added most to NVIDIA in Q2 2024, an estimated $1.12B increase.
- UBS Group's biggest Q2 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $389M.
- UBS Group fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $263M.
- UBS Group's ten largest holdings make up 18% of its $405B portfolio in Q2 2024.
- UBS Group opened 1,231 new positions and closed 1,043 in Q2 2024.
- UBS Group's portfolio value rose 0.81% quarter-over-quarter to $405B.
Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.